About Onconova Therapeutics (NASDAQ:ONTX)
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; a license agreement with SymBio Pharmaceuticals Limited; and a strategic collaboration with Cellectar Biosciences, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680
Debt
Debt-to-Equity RatioN/A
Current Ratio0.49%
Quick Ratio0.49%
Price-To-Earnings
Trailing P/E Ratio-0.19
Forward P/E Ratio-0.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$790,000.00
Price / Sales12.79
Cash FlowN/A
Price / CashN/A
Book Value($1.01) per share
Price / Book-0.51
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-3,061.37%
Return on EquityN/A
Return on Assets-207.61%
Miscellaneous
Employees25
Outstanding Shares19,430,000
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.10. The biopharmaceutical company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.31 million. View Onconova Therapeutics' Earnings History.
When is Onconova Therapeutics' next earnings date?
What price target have analysts set for ONTX?
4 analysts have issued 1-year price targets for Onconova Therapeutics' stock. Their forecasts range from $6.00 to $10.00. On average, they expect Onconova Therapeutics' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.
What are Wall Street analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
- 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (4/19/2018)
- 2. Maxim Group analysts commented, "Summary We discuss in more detail below the meaning of the Interim analysis and the path to approval, including timelines and costs. Can Onconova get there? There are hurdles (aren’t there for most microcap biotech companies?), but we believe they can eventually, based on the fundamental prospects of Rigosertib." (3/26/2018)
- 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 838,242 shares, an increase of 55.3% from the March 15th total of 539,610 shares. Based on an average daily trading volume, of 652,121 shares, the short-interest ratio is presently 1.3 days. Approximately 4.9% of the shares of the stock are short sold.
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include AzurRx BioPharma (AZRX), IntelGenx Technologies (IGXT), Vivus (VVUS), Celsion (CLSN), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), PLx Pharma (PLXP), Chiasma (CHMA), Edge Therapeutics (EDGE), Lipocine (LPCN), Nemus Bioscience (NMUS), Egalet (EGLT), Benitec Biopharma (BNTC), ProPhase Labs (PRPH) and OvaScience (OVAS).
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Dr. Ramesh Kumar, Co-Founder, CEO, Pres & Director (Age 62)
- Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
- Dr. Steven M. Fruchtman, Chief Medical Officer and Sr. VP of R&D (Age 67)
- Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
- Mr. Mark Patrick Guerin, CFO & Principal Accounting Officer (Age 49)
Has Onconova Therapeutics been receiving favorable news coverage?
Media coverage about ONTX stock has trended somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Onconova Therapeutics?
Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of ONTX stock can currently be purchased for approximately $0.5201.
How big of a company is Onconova Therapeutics?
Onconova Therapeutics has a market capitalization of $11.06 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.
How can I contact Onconova Therapeutics?
Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]
MarketBeat Community Rating for Onconova Therapeutics (ONTX)
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Onconova Therapeutics (NASDAQ:ONTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Onconova Therapeutics in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 1,438.17%. The high price target for ONTX is $10.00 and the low price target for ONTX is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.00 | $8.00 | $7.3333 | $7.3333 |
| Price Target Upside: | 1,438.17% upside | 654.72% upside | 326.36% upside | 319.05% upside |
Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History
Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Onconova Therapeutics (NASDAQ:ONTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 12.44%
Onconova Therapeutics (NASDAQ ONTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/8/2018 | 683 Capital Management, Llc | Major Shareholder | Buy | 200,000 | $1.04 | $208,000.00 | |  |
| 4/26/2017 | E Premkumar Reddy | Director | Buy | 119,048 | $2.10 | $250,000.80 | 385,832 | |
| 4/26/2017 | Mark Patrick Guerin | CFO | Buy | 1,429 | $2.10 | $3,000.90 | 5,155 | |
| 4/26/2017 | Ramesh Kumar | Insider | Buy | 23,810 | $2.10 | $50,001.00 | | |
| 2/21/2014 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 143,480 | $8.47 | $1,215,275.60 | 4,518,275 | |
| 2/10/2014 | Ramesh Kumar | CEO | Sell | 33,543 | $15.07 | $505,493.01 | | |
| 2/3/2014 | Ramesh Kumar | CEO | Sell | 60,000 | $15.05 | $903,000.00 | | |
| 1/27/2014 | Michael Hoffman | Director | Buy | 57,295 | $11.92 | $682,956.40 | | |
| 11/22/2013 | Michael Hoffman | Director | Buy | 5,000 | $14.39 | $71,950.00 | | |
| 11/18/2013 | E Premkumar Reddy | Director | Buy | 5,000 | $12.10 | $60,500.00 | 1,278,718 | |
| 11/15/2013 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 19,700 | $11.99 | $236,203.00 | 4,307,500 | |
| 11/15/2013 | Henry Bienen | Director | Buy | 1,400 | $12.17 | $17,038.00 | 14,935 | |
| 11/15/2013 | Ramesh Kumar | CEO | Buy | 1,100 | $12.02 | $13,222.00 | | |
| 7/30/2013 | & Jane Hoffman 2013 De Michael | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | | |
| 7/30/2013 | Ramesh Kumar | CEO | Buy | 6,667 | $15.00 | $100,005.00 | | |
| 7/30/2013 | Thomas J Mckearn | Insider | Buy | 3,333 | $15.00 | $49,995.00 | | |
| 7/30/2013 | Viren Mehta | Director | Buy | 16,667 | $15.00 | $250,005.00 | | |
| 7/25/2013 | E Premkumar Reddy | Director | Buy | 1,000 | $22.72 | $22,720.00 | | |
(Data available from 1/1/2013 forward)
Onconova Therapeutics (NASDAQ ONTX) News Headlines
| Source: |
|
Onconova Therapeutics (NASDAQ:ONTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement
Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
